JP2023518052A5 - - Google Patents
Info
- Publication number
- JP2023518052A5 JP2023518052A5 JP2022555741A JP2022555741A JP2023518052A5 JP 2023518052 A5 JP2023518052 A5 JP 2023518052A5 JP 2022555741 A JP2022555741 A JP 2022555741A JP 2022555741 A JP2022555741 A JP 2022555741A JP 2023518052 A5 JP2023518052 A5 JP 2023518052A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- concentration
- present
- hypoglycemia
- aqueous liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20163408 | 2020-03-16 | ||
| EP20163408.6 | 2020-03-16 | ||
| PCT/EP2021/056651 WO2021185821A1 (en) | 2020-03-16 | 2021-03-16 | Liquid formulations of glucagon analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518052A JP2023518052A (ja) | 2023-04-27 |
| JP2023518052A5 true JP2023518052A5 (cg-RX-API-DMAC10.html) | 2024-03-26 |
| JP7834025B2 JP7834025B2 (ja) | 2026-03-23 |
Family
ID=70008261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555741A Active JP7834025B2 (ja) | 2020-03-16 | 2021-03-16 | グルカゴン類縁体の液体製剤 |
Country Status (23)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312600B2 (en) | 2022-05-30 | 2025-12-01 | Zealand Pharma As | Liquid formulations of amylin analogs |
| WO2025056677A1 (en) | 2023-09-15 | 2025-03-20 | Zealand Pharma A/S | Dasiglucagon for use in the treatment of congenital hyperinsulinism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| NZ704043A (en) * | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| UA121874C2 (uk) | 2015-02-17 | 2020-08-10 | Елі Ліллі Енд Компані | Порошкова назальна композиція для лікування гіпоглікемії |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| WO2019110838A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
-
2021
- 2021-03-16 BR BR112022018462A patent/BR112022018462A2/pt unknown
- 2021-03-16 PH PH1/2022/552457A patent/PH12022552457A1/en unknown
- 2021-03-16 PE PE2022001968A patent/PE20230258A1/es unknown
- 2021-03-16 EP EP21712156.5A patent/EP4121003B1/en active Active
- 2021-03-16 HR HRP20251267TT patent/HRP20251267T1/hr unknown
- 2021-03-16 KR KR1020227031361A patent/KR102956482B1/ko active Active
- 2021-03-16 JP JP2022555741A patent/JP7834025B2/ja active Active
- 2021-03-16 HU HUE21712156A patent/HUE073401T2/hu unknown
- 2021-03-16 UA UAA202203796A patent/UA129439C2/uk unknown
- 2021-03-16 PL PL21712156.5T patent/PL4121003T3/pl unknown
- 2021-03-16 ES ES21712156T patent/ES3041327T3/es active Active
- 2021-03-16 US US17/203,126 patent/US20210283053A1/en not_active Abandoned
- 2021-03-16 WO PCT/EP2021/056651 patent/WO2021185821A1/en not_active Ceased
- 2021-03-16 MX MX2022011227A patent/MX2022011227A/es unknown
- 2021-03-16 CN CN202180021174.4A patent/CN115279341B/zh active Active
- 2021-03-16 IL IL295977A patent/IL295977A/en unknown
- 2021-03-16 RS RS20250960A patent/RS67245B1/sr unknown
- 2021-03-16 CA CA3171184A patent/CA3171184A1/en active Pending
- 2021-03-16 AR ARP210100659A patent/AR121581A1/es unknown
- 2021-03-16 TW TW110109431A patent/TW202200190A/zh unknown
- 2021-03-16 AU AU2021236878A patent/AU2021236878B2/en active Active
-
2022
- 2022-09-09 CL CL2022002472A patent/CL2022002472A1/es unknown
- 2022-10-11 CO CONC2022/0014452A patent/CO2022014452A2/es unknown
-
2024
- 2024-12-20 US US18/989,423 patent/US20250195424A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240342249A1 (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
| US9381247B2 (en) | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain | |
| BE1009408A5 (fr) | Formulations d'analogues de l'insuline. | |
| JP6763777B2 (ja) | 安定なペプチド製剤、および調製のための方法 | |
| RU2320343C2 (ru) | Способ лечения диабета | |
| CN110446496A (zh) | 用于治疗糖尿病的系统、组合物和方法 | |
| HRP20251267T1 (hr) | Tekuće formulacije glukagonskih analoga | |
| US11590205B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
| CA2796567C (en) | Composition comprising insulin and herbal oil for transdermal or transmucosal administration | |
| ZA200500710B (en) | A platform for transdermal formulations (PTF). | |
| NZ791927B2 (en) | Liquid formulations of glucagon analogues | |
| JP7518149B2 (ja) | 高濃度インスリン製剤 | |
| RU2442585C2 (ru) | Способ лечения диабета | |
| WO2024258300A1 (en) | Method of enhancing the systemic hypoglycemic effect of topically applied insulin with the use of prostaglandin analogues: a novel fixed combination eye drop formulation of insulin and prostaglandin analogue for the lowering of blood glucose level | |
| WO2025068976A1 (en) | Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity | |
| HK40101667A (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
| JP2022183378A (ja) | ペメトレキセド製剤 | |
| CN118056841A (zh) | 一种长效胰岛素衍生物及其制备方法和用途 | |
| KR20230055994A (ko) | 당뇨병 또는 당뇨합병증의 치료를 위한 4-헥실레조르시놀의 용도 | |
| JP2004231557A (ja) | エピネフリン含有抗腫瘍剤 | |
| US20260083822A1 (en) | Topical Ocular Insulin Delivery Enhanced by Prostaglandin Analogues | |
| BE1013507A5 (fr) | Formulations d'analogues de l'insuline. | |
| CN109289041A (zh) | 一种维生素d-胰岛素纳米缓释经皮制剂及其制备方法 |